A Phase IB/II Open-Label, Dose Escalation and Expansion Study of Orally Administered VRx-3996 and Valganciclovir in Subjects with Epstein-Barr Virus-Associated Lymphoid Malignancies

Brief Summary

Type:
Lymphomas

Study Type:
Treatment

Phase:
I/II

ClinicalTrials.gov Identifier:
NCT03397706

Study #:
STUDY00141837

Start Date:
May 23, 2018

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03397706

View Complete Trial Details & Eligibility at ClinicalTrials.gov